Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 2;24(11):1950-1961.
doi: 10.1093/neuonc/noac057.

Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials

Adriana Fonseca  1   2 , Cecile Faure-Conter  3 , Matthew J Murray  4   5 , Jason Fangusaro  6 , Shivani Bailey  4 , Stewart Goldman  7 , Soumen Khatua  8 , Didier Frappaz  3 , Gabriele Calaminus  9 , Girish Dhall  10 , James C Nicholson  4 , Eric Bouffet  1 , Ute Bartels  1
Affiliations

Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials

Adriana Fonseca et al. Neuro Oncol. .

Abstract

Background: Central Nervous System Non-Germinomatous Germ Cell Tumors (CNS-NGGCT) are rare but curable tumors. Due to their rarity, patients with treatment failures remain a poorly characterized group with unfavorable outcomes. In this study, we sought to characterize patients with treatment failures in a large, prospectively treated cohort.

Methods: European and North American clinical trials for patients with CNS-NGGCT (SIOP-GCT-96, SFOP-TGM-TC 90/92, COG-ACNS0122, and COG-ACNS1123) were pooled for analysis. Additionally, patients included and treated in the UK and France national registries under strict protocol guidelines were included as an independent, non-overlapping cohort.

Results: A total of 118 patients experienced a treatment failure. Twenty-four patients had progressive disease during therapy, and additional 11 patients were diagnosed with growing teratoma syndrome (GTS). Patients with GTS are significantly younger and present with local failures and negative tumor markers. Eighty-three individuals experienced disease relapses after treatment ended. Patients' metastatic relapses presented significantly earlier than local relapses and were associated with tumor marker elevation (OR: 4.39; P = .026). In our analysis, focal or whole-ventricular radiation therapy was not associated with an increased risk of metastatic relapses.

Conclusions: Herein, we present the largest pooled dataset of prospectively treated patients with relapsed CNS-NGGCT. Our study identified younger age and negative tumor markers to be characteristic of GTS. Additionally, we elucidated that metastatic relapses occur earlier than local relapses are associated with elevated tumor markers and are not associated with the field of radiation therapy. These findings are of utmost importance for the planning of future clinical trials and the implementation of surveillance strategies in these patients.

Keywords: CNS; NGGCT; intracranial germ cell tumors; relapse.

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Treatment schema across clinical trials.
Fig. 2.
Fig. 2.
Consort diagram.
Fig. 3
Fig. 3
Progression-free survival of local vs metastatic relapses.
See this image and copyright information in PMC

Comment in

References

    1. Robertson PL, DaRosso RC, Allen JC. Improved prognosis of intracranial non-germinoma germ cell tumors with multimodality therapy. J Neurooncol. 1997;32(1):71–80. - PubMed
    1. Ogawa K, Toita T, Nakamura K, et al. . Treatment and prognosis of patients with intracranial nongerminomatous malignant germ cell tumors: a multiinstitutional retrospective analysis of 41 patients. Cancer. 2003;98(2):369–376. - PubMed
    1. Fangusaro J, Wu S, MacDonald S, et al. . Phase II trial of response-based radiation therapy for patients with localized CNS nongerminomatous germ cell tumors: a Children’s Oncology Group Study. J Clin Oncol. 2019;37(34):3283–3290. - PMC - PubMed
    1. Calaminus G, Frappaz D, Kortmann RD, et al. . Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol. 2017;19(12):1661–1672. - PMC - PubMed
    1. Goldman S, Bouffet E, Fisher PG, et al. . Phase II trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a Children’s Oncology Group Study. J Clin Oncol. 2015;33(22):2464–2471. - PMC - PubMed

MeSH terms

Substances